With a mortality rate of 20-30% for sepsis and 30-50% for septic shock in developed countries, sepsis represents an enormous public health burden and is responsible for almost 20% of all deaths...
Patient population benefitting most from enibarcimab treatment in septic shock can clearly be defined by two biomarkers, as shown by data presented todayIn the AdrenOSS-2 trial, the respective patient...
Adrenomed AG, a German privately financed clinical-stage biopharmaceutical company, announced that it has received positive feedback from the European Medicines Agency (EMA) regarding the clinical development programme for its lead product candidate, Adrecizumab (INN: enibarcimab). The first-in-class antibody targets the vasoprotective peptide adrenomedullin to restore vascular integrity in patients with early septic shock, a life-threatening condition with very limited treatment options.